A Combined Biomarker of Bright CD38 and MYC ≥55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma.

Abdullah AlsuwaidanPrasad KoduruFranklin FudaJesse Manuel JasoMingyi ChenFlavia RosadoHung S LuuNathan SweedRolando GarciaMeggie DoucetNeil B DesaiKiran A KumarFarrukh T AwanPraveen Ramakrishnan GeethakumariWeina Chen

Published in: American journal of clinical pathology (2022)

Our study demonstrated that the novel biomarker of CD38bright and/or MYC ≥55% is highly predictive of DTHL. Awareness of the advantages and limitations of this screening strategy would facilitate development of a rational diagnostic workflow to provide high-quality patient care.

Keyphrases

high grade
transcription factor
low grade
diffuse large b cell lymphoma
nk cells
electronic health record